Search. Read. Cite.

Easy to search. Easy to read. Easy to cite with credible sources.

Journal of Clinical Lipidology

Year: 2012  |  Volume: 6  |  Issue: 3  |  Page No.: 254 - 255

Changes in Lipoprotein Particle Number with Ezetimibe/Simvastatin Co-administered with Extended-Release Niacin in Patients with Type II Hyperlipidemia

Ngoc-Anh Le, Ran Jin, Andrew M. Tershakovec, David R. Neff, Joanne E. Tomassini, James Otvos and Peter Wilson

Abstract

Intervention with concomitant high-density lipoprotein cholesterol (HDL-C)−raising and low-density lipoprotein cholesterol (LDL-C)−lowering therapies may be beneficial in reducing cardiovascular disease risk. The effects of these therapies on lipoprotein particle numbers have not been well-studied in patients with type II hyperlipidemia (T2HLP). Niacin is currently the most effective agent available for increasing HDL-C and also modestly reduces TG, Lp(a), and LDL-C. In numerous studies, ezetimibe/simvastatin (E/S) was shown to enhance LDL-C lowering and improve other lipids and hsCRP compared with statin therapy in hypercholesterolemic patients.

View Fulltext